Author of

• 15616

  +

  P3.11 - Poster Session/ Palliative and Supportive Care (ID 231)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Palliative and Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15620

    +

    P3.11-004 - Promising Effect of Olanzapine on Chemotherapy-Induced Nausea and Vomiting Uncontrolled with Conventional Antiemetic Therapy (ID 3103)

    09:30 - 09:30  |  Author(s): M. Bando
    • Abstract

    Background:
    Chemotherapy-induced nausea and vomiting (CINV) is still a major adverse effect especially for patients treated with highly emetogenic chemotherapy (HEC). In clinical practice, 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroids are widely used to alleviate emetic episodes during chemotherapy. With those drugs, acute-nausea and vomiting is successfully manageable. However, late-onset nausea and vomiting is sometimes difficult to be controlled and therefore, the promising drugs is needed. Olanzapine is an antipsychotic agent which is approved for schizophrenia and bipolar disorder in Japan. Recently, the combination therapy with olanzapine and the conventional anti-emetic drugs has been reported highly effective to prevent late-onset CIMV after HEC. However, it remains unclear whether olanzapine is really effective for patients who develop acute- or late-onset CIMV after HEC.
    
    Methods:
    All consecutive patients, who were treated with HEC and olanzapine at Jichi Medical University Hospital from January 2014 to December 2014, were included. “Antimetic Response” was defined as the absence of nausea and vomitting, no use of breakthrough antiemetic medications, or increased dietary intake (≧50%). The details of clinical information were reviewed from the medical records .
    
    Results:
    Among 18 patients treated with HEC and olanzapine as antimetic medication, 11 were males and 7 were females, with a median age of 60.5 years (42-74 years). Primary tumors were non-small cell lung cancer in 11 cases, small cell lung cancer in 5, malignant mesothelioma in one case, and embryonal carcinoma in one case. Olanzapine was used for preventing CINV in 8 patients with the previous experience of late-onset CINV and in 2 patients without, for treating late-onset CINV in 6 patients and acute onset CINV in 2 patients. "Antiemetic response" has been observed in 15 patients (83.3%). Among 8 patients previously experiencing late-onset CINV, "Antimetic response" was obtained in 7 patients(87.5%).
    
    Conclusion:
    Our results strongly suggest the olanzapine provides an additional effect on CINV uncontrolled with conventional antiemetic therapy, regardless of whether CINV is acute or chronic.